Skip to main content
. 2020 Jan 28;9(6):2085–2095. doi: 10.1002/cam4.2869

Figure 2.

Figure 2

Kaplan‐Meier estimate of progression‐free survival in patients who received EGFR tyrosine kinase inhibitors (TKIs)